ADMA Biologics Inc (ADMA) Stock Price & How to Invest

ADMA Biologics is an end-to-end biopharmaceutical company focused on plasma-derived therapies. It develops, manufactures, and markets immunoglobulin (IG) products and operates its own plasma-collection centers, giving it control over part of the supply chain that feeds its manufacturing. Its FDA-approved products include Asceniv, an intravenous immune globulin used to treat primary immunodeficiency, Bivigam, a standard intravenous immune globulin, and Nabi-HB for hepatitis B exposure. Asceniv is the company's differentiated, higher-value product and has been the main growth driver, while Bivigam competes in the more crowded standard-IG market.

The investment picture in 2026 became more complicated. In Q1 2026 ADMA reported earnings of about $0.19 per share, up 73% year over year, but total revenue of roughly $114.5 million was essentially flat, and the mix shifted sharply: Asceniv revenue grew about 28% while Bivigam fell about 54%. Citing increased competition, elevated channel inventories, and aggressive pricing in standard IG, ADMA cut its full-year 2026 revenue guidance to roughly $530 to $560 million from a prior view above $635 million, reduced its adjusted net-income outlook, and withdrew previously issued long-term guidance given rapidly evolving competitive dynamics. The result is a company that remains profitable and is still growing its specialty franchise, but whose near-term trajectory got cloudier as standard-IG competition intensified. Owning ADMA means betting that Asceniv and its integrated plasma model can carry growth through a tougher IG market.

The dominant near-term risk is competition and pricing pressure in the standard immunoglobulin market, which drove a 54% drop in Bivigam revenue and led ADMA in 2026 to cut full-year guidance, reduce its net-income outlook, and withdraw long-term targets, citing rapidly evolving competitive dynamics. Elevated channel inventories can delay a recovery in standard-IG sales. Concentration risk is real: growth now leans heavily on a single specialty product, Asceniv, so any stumble there would weigh disproportionately. Plasma-derived manufacturing depends on collecting enough specialized plasma and on regulatory compliance, so supply or FDA issues could disrupt output. As a relatively small biopharma, ADMA is more exposed to single-product and single-market shocks than a diversified drugmaker, and its shares have been volatile, falling sharply after the guidance change. Larger, better-resourced plasma competitors can sustain price competition longer than ADMA.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see ADMA Biologics Inc's investor relations page or your broker.

• Revenue (Q1 2026): ~$114.5 million, roughly flat year over year
• EPS (Q1 2026): ~$0.19, up about 73% year over year
• Product mix trend: Asceniv revenue up ~28%; Bivigam down ~54%
• 2026 revenue guidance: cut to ~$530 to $560 million (from a prior view above $635 million)
• 2026 adjusted net income: reduced to ~$170 to $200 million (from more than $255 million)
• Long-term guidance: withdrawn amid evolving competitive dynamics

Figures are approximate and tied to the asOf date; verify live numbers before acting. ADMA is profitable, so an earnings multiple is meaningful, but the 2026 guidance cut and withdrawn long-term targets make forward estimates less certain than before, so investors should weigh the durability of Asceniv growth against standard-IG competition rather than rely on a single multiple. The mix shift toward specialty product matters more here than headline revenue, which stayed flat.

There are three common ways to get ADMA exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ADMA sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where ADMA fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

ADMA is a profitable, specialized plasma-products maker whose growth engine is its high-value Asceniv immunoglobulin, but 2026 brought a guidance cut, withdrawn long-term targets, and competitive pricing pressure in standard IG. It suits investors who understand a still-growing but suddenly less predictable specialty-biologics story.